551 related articles for article (PubMed ID: 19076171)
1. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.
Kaplan B; Ramirez-Alvarado M; Sikkink L; Golderman S; Dispenzieri A; Livneh A; Gallo G
Br J Haematol; 2009 Mar; 144(5):705-15. PubMed ID: 19076171
[TBL] [Abstract][Full Text] [Related]
2. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease.
Kaplan B; Livneh A; Gallo G
Br J Haematol; 2007 Mar; 136(5):723-8. PubMed ID: 17223908
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease.
Buxbaum J
Hematol Oncol Clin North Am; 1992 Apr; 6(2):323-46. PubMed ID: 1582976
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
Picken MM
Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
[TBL] [Abstract][Full Text] [Related]
6. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties.
Kaplan B; Ramirez-Alvarado M; Dispenzieri A; Zeldenrust SR; Leung N; Livneh A; Gallo G
Clin Chem Lab Med; 2008; 46(3):335-41. PubMed ID: 18254719
[TBL] [Abstract][Full Text] [Related]
7. Proposed reference material for human free immunoglobulin light chain measurement.
Nakano T; Miyazaki S; Shinoda Y; Inoue I; Katayama S; Komoda T; Nagata A
J Immunoassay Immunochem; 2006; 27(2):129-37. PubMed ID: 16711251
[TBL] [Abstract][Full Text] [Related]
8. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion.
Alyanakian MA; Abbas A; Delarue R; Arnulf B; Aucouturier P
Am J Hematol; 2004 Apr; 75(4):246-8. PubMed ID: 15054820
[TBL] [Abstract][Full Text] [Related]
9. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
[TBL] [Abstract][Full Text] [Related]
10. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
Bellotti V; Mangione P; Merlini G
J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin synthesis in primary and myeloma amyloidosis.
Preud'homme JL; Ganeval D; Grünfeld JP; Striker L; Brouet JC
Clin Exp Immunol; 1988 Sep; 73(3):389-94. PubMed ID: 3145161
[TBL] [Abstract][Full Text] [Related]
12. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
13. Interaction between glycosaminoglycans and immunoglobulin light chains.
Jiang X; Myatt E; Lykos P; Stevens FJ
Biochemistry; 1997 Oct; 36(43):13187-94. PubMed ID: 9341206
[TBL] [Abstract][Full Text] [Related]
14. Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
Goldis R; Kaplan B; Arad M; Dispenzieri A; Dasari S; Kukuy OL; Simon AJ; Dori A; Shavit-Stein E; Ziv T; Murray D; Kourelis T; Gertz MA; Dominissini D; Magen H; Muchtar E
Clin Chem Lab Med; 2024 Feb; 62(3):464-471. PubMed ID: 37747270
[TBL] [Abstract][Full Text] [Related]
15. Renal granular monoclonal light chain deposits: morphological aspects in 11 cases.
Noel LH; Droz D; Ganeval D; Grunfeld JP
Clin Nephrol; 1984 May; 21(5):263-9. PubMed ID: 6428790
[TBL] [Abstract][Full Text] [Related]
16. Characterization of amyloidogenic immunoglobulin light chains directly from serum by on-line immunoaffinity isolation.
Bergen HR; Abraham RS; Johnson KL; Bradwell AR; Naylor S
Biomed Chromatogr; 2004 Apr; 18(3):191-201. PubMed ID: 15103706
[TBL] [Abstract][Full Text] [Related]
17. Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition.
Bellotti V; Merlini G
Nephrol Dial Transplant; 1996 Sep; 11(9):1708-11. PubMed ID: 8918605
[No Abstract] [Full Text] [Related]
18. Fibril protein fragmentation pattern in systemic AL-amyloidosis.
Enqvist S; Sletten K; Westermark P
J Pathol; 2009 Dec; 219(4):473-80. PubMed ID: 19771564
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy.
Ronco P; Plaisier E; Mougenot B; Aucouturier P
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1342-50. PubMed ID: 17699367
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
